Etoricoxib

Etoricoxib

Systematic (IUPAC) name
5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridine
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	Not recommended
Legal status	POM (UK)
Routes	Oral
Pharmacokinetic data
Bioavailability	100%
Protein binding	92%
Metabolism	Hepatic, CYP extensively involved (mainly CYP3A4)
Half-life	22 hours
Excretion	Renal (70%) and fecal (20%)
Identifiers
CAS number	202409-33-4 Y
ATC code	M01AH05
PubChem	CID 123619
DrugBank	DB01628
ChemSpider	110209 Y
UNII	WRX4NFY03R Y
KEGG	D03710 Y
ChEBI	CHEBI:6339 Y
ChEMBL	CHEMBL416146 Y
Chemical data
Formula	C18H15ClN2O2S
Mol. mass	358.842 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3 Y Key:MNJVRJDLRVPLFE-UHFFFAOYSA-N Y
Y(what is this?)  (verify)

Etoricoxib (brand name'NUSHINMASCOT HEALTH SERIES Arcoxia worldwide; also Algix and Tauxib in Italy, Etosaid in India) is a COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1) from Merck & Co. Currently it is approved in more than 70 countries worldwide but not in the US, where the Food and Drug Administration (FDA) requires additional safety and efficacy data for etoricoxib before it will issue approval. Current therapeutic indications are: treatment of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Note that approved indications differ by country.

Like any other COX-2 selective inhibitor ("coxib"), etoricoxib selectively inhibits isoform 2 of the enzyme cyclo-oxigenase (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid. Among the different functions exerted by PGs, their role in the inflammation cascade should be highlighted. COX-2 selective inhibitors showed less marked activity on type 1 cycloxigenase compared to traditional non-steroidal anti-inflammatory drugs (NSAID). This reduced activity is the cause of reduced gastrointestinal side effects, as demonstrated in several large clinical trials performed with different coxibs.^[1][2]

Some clinical trials and meta-analysis showed that treatment with some coxibs (in particular rofecoxib) led to increased incidence of adverse cardiovascular events compared to placebo. Because of these results, some drugs were withdrawn from the market (rofecoxib, in September 2004 and valdecoxib in April 2005). In addition, the FDA and EMA (USA and European Community health authorities respectively) started a revision process of the entire class of both NSAID and COX-2 inhibitors.

The FDA concluded its revision on April 6, 2005: the final document can be found here.

The EMA concluded its revision on June 27, 2005: the final document can be found here.

On April 27, 2007, the Food and Drug Administration issued Merck a "non-approvable letter" for etoricoxib. The letter said Merck needs to provide more test results showing that the drug's benefits outweigh its risks before it has another chance of getting approved.

References

1. ^ (VIGOR study on The New England Journal of Medicine - NEJM)
2. ^ (MEDAL study on The Lancet)

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.v · Categories: COX-2 inhibitors Pyridines Organochlorides Musculoskeletal system drug stubs Wikimedia Foundation. 2010. Игры ⚽ Поможем решить контрольную работу Fife Symington III Rhymney Valley Look at other dictionaries: Etoricoxib — Étoricoxib Étoricoxib Général Nom IUPAC 5 chloro 6 methyl 3 [4 (methylsulfonyl)phenyl] 2,3 bipyridine N …   Wikipédia en Français Étoricoxib — Général Nom IUPAC 5 chloro 6 méthyl 3 [4 (méthylsulfonyl)phényl] 2,3 bipyridine No CAS …   Wikipédia en Français etoricoxib — anti inflamatorio no esteroidíco, inhibidor selectivo de la COX 2, que se utiliza en el tratamiento de la artritis reumatoide fórmula química [véase http://www.iqb.es/diccio/e/et.htm#etoricoxib] Diccionario ilustrado de Términos Médicos.. Alvaro… …   Diccionario médico Etoricoxib — Strukturformel Allgemeines Freiname Etoricoxib Andere Namen …   Deutsch Wikipedia etoricoxib — etor·i·cox·ib (e tor″ĭ kokґsib) a nonsteroidal antiinflammatory drug of the COX 2 inhibitors group, used for symptomatic treatment of osteoarthritis and rheumatoid arthritis; administered orally …   Medical dictionary 202409-33-4 — Étoricoxib Étoricoxib Général Nom IUPAC 5 chloro 6 methyl 3 [4 (methylsulfonyl)phenyl] 2,3 bipyridine N …   Wikipédia en Français Arcoxia — Étoricoxib Étoricoxib Général Nom IUPAC 5 chloro 6 methyl 3 [4 (methylsulfonyl)phenyl] 2,3 bipyridine N …   Wikipédia en Français C18H15N2O2S — Étoricoxib Étoricoxib Général Nom IUPAC 5 chloro 6 methyl 3 [4 (methylsulfonyl)phenyl] 2,3 bipyridine N …   Wikipédia en Français Discovery and development of cyclooxygenase 2 inhibitors — Cyclooxygenases are enzymes that take part in a complex biosynthetic cascade that results in the conversion of polyunsaturated fatty acids to prostaglandins and thromboxane(s).[1] Their main role is to catalyze the transformation of arachidonic… …   Wikipedia Rofecoxib — Systematic (IUPAC) name 4 (4 methylsulfonylphenyl) 3 phenyl 5H furan 2 one Clinical data Pregnancy cat. C ( …   Wikipedia 18+ © Academic, 2000-2024 Contact us: Technical Support, Advertising Dictionaries export, created on PHP, Joomla, Drupal, WordPress, MODx. Mark and share Search through all dictionaries Translate… Search Internet Share the article and excerpts Direct link … Do a right-click on the link above and select “Copy Link”